Online citations, reference lists, and bibliographies.
← Back to Search

Dose-dependent Pulmonary Toxicity After Postoperative Intensity-modulated Radiotherapy For Malignant Pleural Mesothelioma.

D. Rice, W. Smythe, Z. Liao, T. Guerrero, J. Chang, M. McAleer, M. Jeter, A. Correa, A. Vaporciyan, H. Liu, R. Komaki, K. Forster, C. Stevens
Published 2007 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE To determine the incidence of fatal pulmonary events after extrapleural pneumonectomy and hemithoracic intensity-modulated radiotherapy (IMRT) for malignant pleural mesothelioma. METHODS AND MATERIALS We retrospectively reviewed the records of 63 consecutive patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy and IMRT at the University of Texas M. D. Anderson Cancer Center. The endpoints studied were pulmonary-related death (PRD) and non-cancer-related death within 6 months of IMRT. RESULTS Of the 63 patients, 23 (37%) had died within 6 months of IMRT (10 of recurrent cancer, 6 of pulmonary causes [pneumonia in 4 and pneumonitis in 2], and 7 of other noncancer causes [pulmonary embolus in 2, sepsis after bronchopleural fistula in 1, and cause unknown but without pulmonary symptoms or recurrent disease in 4]). On univariate analysis, the factors that predicted for PRD were a lower preoperative ejection fraction (p = 0.021), absolute volume of lung spared at 10 Gy (p = 0.025), percentage of lung volume receiving >or=20 Gy (V(20); p = 0.002), and mean lung dose (p = 0.013). On multivariate analysis, only V20 was predictive of PRD (p = 0.017; odds ratio, 1.50; 95% confidence interval, 1.08-2.08) or non-cancer-related death (p = 0.033; odds ratio, 1.21; 95% confidence interval, 1.02-1.45). CONCLUSION The results of our study have shown that fatal pulmonary toxicities were associated with radiation to the contralateral lung. V20 was the only independent determinant for risk of PRD or non-cancer-related death. The mean V20 of the non-PRD patients was considerably lower than that accepted during standard thoracic radiotherapy, implying that the V20 should be kept as low as possible after extrapleural pneumonectomy.
This paper references
10.1016/J.IJROBP.2005.06.046
Influence of adjacent low-dose fields on tolerance to high doses of protons in rat cervical spinal cord.
Hendrik P. Bijl (2006)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/J.IJROBP.2005.08.002
Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
S. Wang (2006)
10.1016/J.IJROBP.2004.08.025
Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy.
M. Fay (2005)
10.1016/S0360-3016(02)04150-0
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.
K. Forster (2003)
10.1016/S0360-3016(99)00247-3
Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer.
A. Eisbruch (1999)
10.1016/J.IJROBP.2005.03.026
Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study.
E. Yorke (2005)
10.1016/J.IJROBP.2006.03.012
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
A. Allen (2006)
10.1067/MTC.2002.125817
Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
T. T. Lee (2002)
10.1097/00130404-200311000-00008
Promising Early Local Control of Malignant Pleural Mesothelioma Following Postoperative Intensity Modulated Radiotherapy (IMRT) to the Chest
A. Ahamad (2003)
10.1007/BF02306613
Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
H. Pass (2006)
10.1016/S0360-3016(01)02589-5
Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation.
A. Della Volpe (2002)
10.1016/0360-3016(87)90173-8
Technique for external beam treatment for mesothelioma.
G. Kutcher (1987)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1016/S0360-3016(99)00183-2
Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)
M. Graham (1999)
10.1016/S0360-3016(03)00287-6
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.
S. Yajnik (2003)
10.1016/J.IJROBP.2006.01.051
Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis.
F. Kong (2006)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1016/S0003-4975(99)01038-3
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
V. Rusch (1999)
10.1016/J.IJROBP.2004.12.023
Challenges in defining radiation pneumonitis in patients with lung cancer.
Z. Koçak (2005)
10.1016/J.ATHORACSUR.2005.06.014
Extended surgical staging for potentially resectable malignant pleural mesothelioma.
D. Rice (2005)
10.1200/jco.2005.23.16_suppl.7178
Extrapleural pneumonectomy followed by IMRT: Results of a phase I/II study
C. Stevens (2005)
10.1016/S0360-3016(98)00196-5
Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients.
S. L. Kwa (1998)
10.1016/S0167-8140(99)00100-0
Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer.
M. Zelefsky (2000)
10.1016/S0360-3016(01)01685-6
Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer.
M. L. Hernando (2001)
10.1016/S0003-4975(96)01228-3
Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
E. Baldini (1997)
10.1016/S0360-3016(02)04151-2
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
A. Ahamad (2003)
10.1016/J.LUNGCAN.2005.03.031
Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the palliative treatment of malignant mesothelioma of the pleura: the Heidelberg experience.
M. Muenter (2005)



This paper is referenced by
10.1097/JTO.0b013e318272601f
Tomotherapy after Pleurectomy/Decortication or Biopsy for Malignant Pleural Mesothelioma Allows the Delivery of High Dose of Radiation in Patients with Intact Lung
E. Minatel (2012)
10.1016/j.ijrobp.2017.04.025
Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma.
E. Yorke (2017)
10.1053/j.semtcvs.2013.10.004
Current readings: improvements in intensity-modulated radiation therapy for malignant pleural mesothelioma.
Kenneth E. Rosenzweig (2013)
10.1016/j.ijrobp.2009.06.091
Radiation dose-volume effects in the lung.
L. Marks (2010)
10.7759/cureus.1705
Proton Therapy for Malignant Pleural Mesothelioma: A Three Case Series Describing the Clinical and Dosimetric Advantages of Proton-Based Therapy
Howard D. Lee (2017)
Orphanet Journal of Rare Diseases Malignant Mesothelioma Disease Name and Definition Epidemiology and Aetiology
Alastair J. Moore ()
10.1016/j.brachy.2009.08.009
High-dose-rate surface brachytherapy to boost elongated, curvilinear incisional scars after extrapleural pneumonectomy for malignant pleural mesothelioma treated with adjuvant intensity-modulated radiation therapy.
Laura A. Doyle (2010)
10.1016/j.critrevonc.2016.05.004
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
10.1016/j.ijrobp.2010.12.073
Intensity-modulated radiotherapy might increase pneumonitis risk relative to three-dimensional conformal radiotherapy in patients receiving combined chemotherapy and radiotherapy: a modeling study of dose dumping.
I. S. Vogelius (2011)
10.2217/fon.09.7
Malignant pleural mesothelioma.
R. Stahel (2009)
10.1016/j.adro.2019.08.010
Fatal Radiation Pneumonitis: Literature Review and Case Series
Stephen T. Keffer (2020)
10.1007/978-3-319-40618-3_37
Malignant pleural mesothelioma.
D. Ettinger (2012)
10.1155/2019/4568958
Dosimetric Comparison of Lung-Sparing Radiation Therapy between Volumetric Arc Therapy and Helical Tomotherapy for Unresectable Malignant Pleural Mesothelioma
Berrin Pehlivan (2019)
10.1016/j.ijrobp.2011.09.027
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
K. Rosenzweig (2012)
10.3978/j.issn.2225-319X.2012.10.07
Novel radiation therapy approaches in malignant pleural mesothelioma.
A. Rimner (2012)
10.1016/j.lungcan.2011.05.012
Mesothelioma at era of helical tomotherapy: results of two institutions in combining chemotherapy, surgery and radiotherapy.
A. Sylvestre (2011)
10.1016/j.ijrobp.2009.11.006
Proton therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy.
J. Krayenbuehl (2010)
10.1097/JTO.0000000000000346
Intensity-modulated radiotherapy for lung cancer: current status and future developments.
C. Chan (2014)
10.1016/B978-0-323-24098-7.00014-9
Chapter 14 – Late Effects after Radiation
Michael T Milano (2016)
10.1007/978-3-319-28761-4_20
Modern Radiotherapy Techniques in Malignant Pleural Mesothelioma
Gokhan Ozyigit (2016)
10.1053/j.semtcvs.2014.08.003
Novel induction therapies for pleural mesothelioma.
Laura L Donahoe (2014)
10.1016/j.ijrobp.2011.11.057
Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy.
P. Patel (2012)
10.1007/s13566-017-0299-2
Radiation therapy for localized malignant pleural mesothelioma: a propensity score-matched analysis of the National Cancer Data Base
N. Ohri (2017)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1053/j.semtcvs.2009.06.009
Radiation therapy options for malignant pleural mesothelioma.
E. Baldini (2009)
10.5772/55292
Mesothelioma: An Evidence-Based Review
Julie Goudreault (2013)
An Update on Biomarkers and Treatment
Mandira Ray (2015)
10.1120/jacmp.v17i3.6199
Geometric dose prediction model for hemithoracic intensity‐modulated radiation therapy in mesothelioma patients with two intact lungs
LiCheng Kuo (2016)
10.1016/J.THORSURG.2020.08.006
Radiation Therapy for Malignant Pleural Mesothelioma.
K. Rosenzweig (2020)
10.1186/1750-1172-3-34
Malignant mesothelioma
A. Moore (2008)
10.4161/cbt.10.5.12616
Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma
K. Du (2010)
10.1016/j.prro.2018.12.008
Dosimetric Correlates of Pulmonary Toxicity in Patients with Malignant Pleural Mesothelioma Receiving Radiation Therapy to the Intact Lungs.
M. Thompson (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar